WO2012080984A3 - Comprimé pharmaceutique à libération contrôlée pour administration par voie orale - Google Patents

Comprimé pharmaceutique à libération contrôlée pour administration par voie orale Download PDF

Info

Publication number
WO2012080984A3
WO2012080984A3 PCT/IB2011/055720 IB2011055720W WO2012080984A3 WO 2012080984 A3 WO2012080984 A3 WO 2012080984A3 IB 2011055720 W IB2011055720 W IB 2011055720W WO 2012080984 A3 WO2012080984 A3 WO 2012080984A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral administration
controlled
active principle
release pharmaceutical
pharmaceutical tablet
Prior art date
Application number
PCT/IB2011/055720
Other languages
English (en)
Spanish (es)
Other versions
WO2012080984A2 (fr
Inventor
Héctor SENOSIAIN ARROYO
María Angélica ARZOLA PANIAGUA
Gustavo BARRANCO HERNÁNDEZ
Original Assignee
Laboratorios Senosiain S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012080984(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain S.A. De C.V. filed Critical Laboratorios Senosiain S.A. De C.V.
Priority to RU2013127408/15A priority Critical patent/RU2603469C2/ru
Priority to BR112013014963A priority patent/BR112013014963A2/pt
Publication of WO2012080984A2 publication Critical patent/WO2012080984A2/fr
Publication of WO2012080984A3 publication Critical patent/WO2012080984A3/fr
Priority to CR20130288A priority patent/CR20130288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des compositions pharmaceutiques sous forme de comprimés pour l'administration par voie orale, contenant un principe actif et des excipients pharmaceutiquement acceptables. Ces comprimés sont caractérisés en ce qu'une partie du principe active est libérée immédiatement, et une autre partie du principe actif se trouve dans un système de matrice polymère de diffusion qui permet une libération retardée du principe actif.
PCT/IB2011/055720 2010-12-17 2011-12-16 Comprimé pharmaceutique à libération contrôlée pour administration par voie orale WO2012080984A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU2013127408/15A RU2603469C2 (ru) 2010-12-17 2011-12-16 Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
BR112013014963A BR112013014963A2 (pt) 2010-12-17 2011-12-16 comprimido farmacêutico de liberação controlada para administração oral
CR20130288A CR20130288A (es) 2010-12-17 2013-06-13 Comprimido farmacéutico de liberación controlada para administración oral

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2010/014153 2010-12-17
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.

Publications (2)

Publication Number Publication Date
WO2012080984A2 WO2012080984A2 (fr) 2012-06-21
WO2012080984A3 true WO2012080984A3 (fr) 2012-08-16

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/055720 WO2012080984A2 (fr) 2010-12-17 2011-12-16 Comprimé pharmaceutique à libération contrôlée pour administration par voie orale

Country Status (11)

Country Link
BR (1) BR112013014963A2 (fr)
CL (1) CL2013001707A1 (fr)
CO (1) CO6721021A2 (fr)
CR (1) CR20130288A (fr)
DO (1) DOP2013000136A (fr)
EC (1) ECSP13012766A (fr)
GT (1) GT201300154A (fr)
MX (1) MX2010014153A (fr)
PE (1) PE20140675A1 (fr)
RU (1) RU2603469C2 (fr)
WO (1) WO2012080984A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (fr) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Alignement d'un patient à l'intérieur d'un appareil d'imagerie par résonance magnétique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035177A2 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Melanges polymeres optimaux pour comprimes a retention gastrique
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003053402A1 (fr) * 2001-12-20 2003-07-03 Pharmacia Corporation Formes dosifiees a liberation soutenue d'ordre zero et procede de production associe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035177A2 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Melanges polymeres optimaux pour comprimes a retention gastrique
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003053402A1 (fr) * 2001-12-20 2003-07-03 Pharmacia Corporation Formes dosifiees a liberation soutenue d'ordre zero et procede de production associe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS CHEMICAL ABSTRACTS SERVICE; accession no. 008:104222 *
PEI, ZHI-GIANG ET AL.: "Optimization of levofloxacin hydrochloride sustained-release tablets by central composite design", YAOXUE JINZHAN, vol. 31, no. 11, 2007, pages 508 - 512 *

Also Published As

Publication number Publication date
CL2013001707A1 (es) 2014-01-10
CO6721021A2 (es) 2013-07-31
ECSP13012766A (es) 2013-09-30
BR112013014963A2 (pt) 2016-09-13
PE20140675A1 (es) 2014-06-25
GT201300154A (es) 2014-05-07
CR20130288A (es) 2013-08-13
MX2010014153A (es) 2012-06-18
RU2013127408A (ru) 2015-01-27
WO2012080984A2 (fr) 2012-06-21
RU2603469C2 (ru) 2016-11-27
DOP2013000136A (es) 2013-10-15

Similar Documents

Publication Publication Date Title
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
MX337603B (es) Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
NZ599031A (en) A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2011076749A3 (fr) Forme solide de dosage pharmaceutique
WO2009088414A3 (fr) Formes posologiques pharmaceutiques orales
WO2009063222A3 (fr) Compositions solides
PH12014501408A1 (en) Immediate release multi unit pellet system
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
UA116334C2 (uk) Тверді форми дозування бендамустину
WO2010127205A3 (fr) Formulations de combinaison de médicament à dose fixe
WO2011104652A3 (fr) Compositions vétérinaires
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2011111027A3 (fr) Formulation de comprimé oral dispersible à libération retardée
CA2863376A1 (fr) Comprimes gastro-resistants
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2013106068A3 (fr) Compositions thérapeutiques de préparations déterminées à base de plantes, et leurs utilisations
PE20131035A1 (es) Formulacion de nevirapina de liberacion prolongada
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2010081722A3 (fr) Comprimés à désintégration orale pour traiter la douleur
WO2010079433A3 (fr) Composition pharmaceutique qui comprend un inhibiteur de la dipeptidyl peptidase-iv
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
WO2012080984A3 (fr) Comprimé pharmaceutique à libération contrôlée pour administration par voie orale
WO2012068076A3 (fr) Formulations pharmaceutiques contenant des médicaments solubles

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2013001707

Country of ref document: CL

Ref document number: 001406-2013

Country of ref document: PE

Ref document number: CR2013-000288

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13145004

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2013127408

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 11848659

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013014963

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013014963

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130614